DCM
LXRX icon

Delpha Capital Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Delpha Capital Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-4,328
Closed -$43K – 744
2017
Q4 		$43K Buy
+4,328
New +$45K 0.05% 377

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UIM
USS Investment Management London, United Kingdom $27.8B AUM 39.42% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return

Delpha Capital Management's LXRX Position: Q1 2018 in Review

Delpha Capital Management sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2018, closing a stake of 4,328 shares — an estimated $43K sold.

Delpha Capital Management first reported a position in LXRX in Q4 2017 and held it in 1 quarter. The position peaked at $43K in Q4 2017. 126 funds tracked by Wall St. Rank hold LXRX as of Q1 2018.

  • Delpha Capital Management reported no remaining Lexicon Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 4,328 Lexicon Pharmaceuticals shares in Q1 2018, an estimated $43K.
  • Delpha Capital Management first reported a position in Lexicon Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's Lexicon Pharmaceuticals position peaked at $43K in Q4 2017.
  • 126 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.